neuMirRx Obtains Rights To Nanoparticle Drug Technology
neuMirRx Corp today welcomed the issuance of U.S. patent 7,345,093, entitled "Methods for Enhancing Solubility of Compounds" which covers novel formulation methods to enhance the solubility of hydrophobic compounds. The rights to this patent and related proprietary technology, the neuNanoParticle, have been obtained by neuMirRx Corp through an exclusive license arrangement with Formatech, Inc. of Andover, Massachusetts.
"The proprietary neuNanoParticle technology effectively solubilizes pharmaceutical compounds in micellar formulations containing fatty acids and/or fatty alcohols and further results in much higher maximum tolerated doses (MTD)," said Ben Isaacs, Ph.D., CEO, neuMirRx Corp. "In addition to addressing significant excipient related safety issues, the technology also delivers drug formulations that are compatible with parenteral (both liquid and lyophilized), oral, pulmonary and topical routes of administration," he added.
"We are applying this novel technology to several commercially successful drugs in markets that welcome and support safer, more effective drug product formulation. This includes drugs such as Taxotere, Taxol, Diprivan and Cyclosporin," said Dr. Issacs. "Our acquisition of this technology demonstrates our company's continuing mission to chart a new course in drug delivery for human healthcare," he added.
The Andover, Massachusetts based company, neuMirRx Corp, seeks to apply this patented technology to approved pharmaceutical products to develop and commercialize Qualiceuticals - next generation quality pharmaceutical products with enhanced safety and efficacy profiles. neuMirRx also seeks to in-license and/or partner to extend the neuNanoParticle advantage to novel pharmaceutical compounds or new chemical entities.